ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BOLT / dividends
JAGX (28) HIND (29) BFRI (26) BIVI (32) ⌘ Pro Terminal →

Bolt Biotherapeutics Inc. (BOLT) Dividend Safety Gauge & 10-Year DRIP Compounder

$6.24 -5.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.17

Bolt Biotherapeutics Inc. (BOLT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $12.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BOLT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BOLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Bolt Biotherapeutics Inc. (NASDAQ: BOLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $6.24 (-5.31% 1D, market cap $12.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1016 tracked Health Care issuers, BOLT ranks #550 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BOLT compare to JAGX and HIND in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, JAGX (Jaguar Health Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M) and HIND (Vyome Holdings Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M). Among the 5-stock peer group, BOLT leads on earnings multiple (N/A) while BOLT leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BOLT?
▼

Per BOLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001641281), Bolt Biotherapeutics Inc. generated $7.7M in revenue (+0.1% YoY), -$33.4M in net income, and -$39.9M in free cash flow against $56.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.17 (-1.15%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (37/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • D-
025507510037
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (4)Whales (13)SEC (8)Macro (9)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-9.5% Base Target
$8 Bull$6 Base$4 Bear
📬 FREE BOLT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BOLT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (37/100 Composite)
🔍 WHY BOLT SCORES 37/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (35% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (24% of score)

FRED Regime × Technicals: 67% of 52W Range • RSI-14 at 72.4 (OVERBOUGHT (>70))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
29
Grade E$4.28+0.7% Next Q
Q2 (-2Q)
32
Grade E$4.31+47.8% Next Q
Q3 (-1Q)
34
Grade E$6.37-2% Next Q
Current
37
Grade D-$6.24-8.1% Hist 90D α
Trajectory: E (29) → D- (37)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BOLT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BOLT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.25) and Max Pain ($6.55) forces dealer call-delta covering toward $8.17.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BOLT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BOLT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 37%NO 63%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $307/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BOLT)

  • ✓Walkthrough of BOLT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BOLT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +23.32%📐 HORIZONTAL RANGE
2026-11-03O $6.36H $6.59L $6.24C $6.24VOL 249.9K
RES: $7.92SUP: $3.06SMA50: $4.25SMA200: $4.51
$8.11$6.75$5.39$4.04$2.68RES $7.92SUP $3.06$6.242026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BOLT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BOLT Butterfly Map → + Track BOLT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +0.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BOLT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BOLT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BOLT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BOLT)

Health Care Rank #550 of 1016 ⚔️ JAGX vs BOLT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BOLT vs. JAGX, HIND, BFRI, BIVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bolt Biotherapeutics Inc. (BOLT) ranks #550 by composite RQD confidence (37/100, grade D-) and #869 by equity capitalization ($12.7M). Within this direct 5-issuer industry benchmark cohort, BOLT leads on earnings valuation at N/A trailing P/E, while BOLT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BOLT currently leads its immediate peer cohort in composite quantitative strength at 37/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BOLT ACTIVE
Bolt Biotherapeutics Inc.
D- 37/100 — — -35.0% -5.31% $12.7M Benchmark Subject
JAGX
Jaguar Health Inc.
E 28/100 — 67.2% -35.0% -45.43% $12.6M /jagx-vs-bolt →
HIND
Vyome Holdings Inc.
E 29/100 — 68.4% -35.0% -2.22% $12.6M /hind-vs-bolt →
BFRI
Biofrontera Inc.
E 26/100 — — -35.0% -0.32% $13.0M /bfri-vs-bolt →
BIVI
BioVie Inc. (Class A)
E 32/100 — — -35.0% -4.20% $12.4M /bivi-vs-bolt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001641281 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bolt Biotherapeutics Inc. (BOLT) reported GAAP revenue of $7.7M (+0.1% vs. FY2024 revenue of $7.7M , and -2.3% cumulative change since FY2023) , GAAP net income of -$33.4M, operating cash flow of -$39.9M, and free cash flow of -$39.9M (+34.9% YoY). On the balance sheet, BOLT closed FY2025 with $56.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $7.7M -$33.4M -$39.9M -$39.9M $56.7M —
FY2024 (FY) 2024-12-31 $7.7M -$63.1M -$61.3M -$61.3M $99.6M —
FY2023 (FY) 2023-12-31 $7.9M -$69.2M -$69.5M -$69.5M — —

3. BOLT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BOLT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Bolt Biotherapeutics Inc. (NASDAQ: BOLT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $6.24 (-5.31% 1D, market cap $12.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 3/20. Across 1016 tracked Health Care issuers, BOLT ranks #550 in composite RQD confidence.

How does BOLT compare to JAGX and HIND in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BOLT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, JAGX (Jaguar Health Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M) and HIND (Vyome Holdings Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $12.6M). Among the 5-stock peer group, BOLT leads on earnings multiple (N/A) while BOLT leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BOLT?

Per BOLT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001641281), Bolt Biotherapeutics Inc. generated $7.7M in revenue (+0.1% YoY), -$33.4M in net income, and -$39.9M in free cash flow against $56.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BOLT trading relative to its 50-day, 200-day, and 52-week technical levels?

BOLT last traded at $6.24 (-5.31% on volume of 50,410 shares), positioning the stock +46.82% above its 50-day simple moving average ($4.25) and +38.36% above its 200-day simple moving average ($4.51). Across its 52-week range of $3.10 to $7.78, BOLT sits at the 67.1% percentile with a 14-day RSI of 72.4 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($5.46 to $7.02).

Direct Sub-Reports: BOLT RQD Cockpit BOLT 12M Forecast BOLT Earnings & Move BOLT Dividends & DRIP BOLT Insiders & 13F BOLT Whale Options BOLT Profit Sankey BOLT News & Why
ROARABLE RATING BRIEF • RQD 37/100 (D-) ✓ SEC XBRL & RQD VERIFIED

BOLT — Bolt Biotherapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Bolt Biotherapeutics Inc. (BOLT) earns a live Roarable RQD composite score of 37/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $6.24 (-5.31% 1D, market capitalization $12.7M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Bolt Biotherapeutics Inc. (BOLT) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry.. Reported revenue was $7.7M for FY 2025 and $7.7M for FY 2024. Per recent news, the company announced an acquisition of Prana Therapies alongside a $120 Million concurrent private placement to advance PRA-216 in inflammatory indications.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bolt Biotherapeutics Inc. (BOLT) reported $7.7M in annual revenue (up from $7.7M in FY2024, +0.1% YoY) and -$33.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($7.9M revenue, -$69.2M net income) through FY2025, BOLT scaled operating cash flow to -$39.9M and free cash flow to -$39.9M, backed by $56.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D- • RQD 37/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 13/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $3.10 – $7.78 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Investors should note that the acquisition of Prana Therapies and the PRA-216 program are the only identifiable ripple pathways in the news, and their operational interdependencies are not specified in source data.

  • Key Question #1: Can BOLT sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $7.7M and free cash flow of -$39.9M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BOLT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BOLT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bolt Biotherapeutics Inc. (BOLT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BOLT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BOLT Bull vs. Bear Conversation Board — What's Your Call at $6.24?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BOLT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BOLT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $7.64 (+15.9%)
📌 Pinned Debate

Institutional accumulation (14/20 whale 13F flow) and a $120M financing alongside the Prana acquisition give the company fresh capital

Picked up a starter position in BOLT in my $100K Virtual Cash book at $6.59. Institutional accumulation (14/20 whale 13F flow) and a $120M financing alongside the Prana acquisition give the company fresh capital to advance PRA-216.. Trading inside a $3.10–$7.78 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator 🐂 BULL

@BearTrap_Alert Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $5.34 (-19.0%)
Spot @ $6.59

A -35% ROIC, 0% FCF yield, and a Piotroski F-Score of 2/9 indicate a cash-consuming business with weak forensic balance sheet quality.

Careful chasing BOLT at $6.59. A -35% ROIC, 0% FCF yield, and a Piotroski F-Score of 2/9 indicate a cash-consuming business with weak forensic balance sheet quality.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $5.34 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%